| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2016.155 |
| P698 | PubMed publication ID | 27220666 |
| P2093 | author name string | W Kolanus | |
| D Wolf | |||
| P Brossart | |||
| A Heine | |||
| J Trebicka | |||
| J Rudolph | |||
| T Quast | |||
| P2860 | cites work | CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway | Q28209767 |
| Non-muscle myosin II takes centre stage in cell adhesion and migration | Q28262326 | ||
| CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs | Q28594485 | ||
| Rapid leukocyte migration by integrin-independent flowing and squeezing | Q29620345 | ||
| Dendritic-cell trafficking to lymph nodes through lymphatic vessels | Q33989067 | ||
| The V617F JAK2 mutation and the myeloproliferative disorders | Q36312018 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 | ||
| JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Differential requirement for ROCK in dendritic cell migration within lymphatic capillaries in steady-state and inflammation. | Q50505877 | ||
| Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). | Q50860871 | ||
| Myelofibrosis with myeloid metaplasia | Q73712758 | ||
| Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation | Q77353738 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| P433 | issue | 10 | |
| P921 | main subject | dendritic cell | Q506253 |
| ruxolitinib | Q7383611 | ||
| P304 | page(s) | 2119-2123 | |
| P577 | publication date | 2016-05-25 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. | |
| P478 | volume | 30 |
| Q91587430 | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
| Q91949140 | Myeloproliferative and lymphoproliferative disorders: State of the art |
| Q39015300 | Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management |
| Q38938526 | Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. |
| Q91598124 | Targeting senescent cells: approaches, opportunities, challenges |
| Q41716360 | Tumor-related interleukins: old validated targets for new anti-cancer drug development |
Search more.